• SPX
  • $5,695.94
  • -0.96 %
  • -$55.13
  • DJI
  • $41,954.24
  • -0.94 %
  • -$398.51
  • N225
  • $38,896.85
  • -1.11 %
  • -$435.82
  • FTSE
  • $8,303.62
  • 0.28 %
  • $22.99
  • IXIC
  • $17,923.90
  • -1.18 %
  • -$213.95
Can-Fite BioPharma Ltd. (CANF) Stock Price, News & Analysis

Can-Fite BioPharma Ltd. (CANF) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.00

$0.03

(1.54%)

Day's range
$1.94
Day's range
$2.04
50-day range
$1.87
Day's range
$3.71
  • Country: IL
  • ISIN: US13471N3008
52 wk range
$1.81
Day's range
$4.69


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -21.63
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (CANF)
  • Company Can-Fite BioPharma Ltd.
  • Price $2.00
  • Changes Percentage (1.54%)
  • Change $0.03
  • Day Low $1.94
  • Day High $2.04
  • Year High $4.69

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/28/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $10.00
  • High Stock Price Target $10.00
  • Low Stock Price Target $10.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.00
  • Trailing P/E Ratio -0.82
  • Forward P/E Ratio -0.82
  • P/E Growth -0.82
  • Net Income $-7,634,000

Income Statement

Quarterly

Annual

Latest News of CANF

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.